Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Director | August 04, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 27,000 |
Reported balance
After 2026-08-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 27,000 · Balance 27,000 F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 18, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectAlpine ImmunoSciences, L.P. | 0 |
Reported balance
After 2024-05-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-18 · Other · Disposed 2,627,157 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 96,000 |
Reported balance
After 2024-05-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-05-20 · Disposition to issuer · Disposed 13,245 · Balance 96,000 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 96,000 · Balance 0 F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 70,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2027-03-13 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 247,951 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2027-04-11 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 208,916 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 200,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2030-01-22 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 270,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-05-20 · Disposition to issuer · Disposed 255,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F11: One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-05-20 · Disposition to issuer · Disposed 215,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F12: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.55 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-05-20 · Disposition to issuer · Disposed 336,755 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F13: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.33 · Expires 2034-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-05-20 · Disposition to issuer · Disposed 240,000 · Balance 0 F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F14: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F4: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5: Includes 96,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date.
F6: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration.
F7: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F8: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F9: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F10: (Continued from Footnote 9) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F11: One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F12: One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F13: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
F14: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2021 Filed Jun 29, 2021 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 9,473 | $10.01 | $94,865.46 |
DisclosureSEC source: 0001626199-21-000087 · wf-form4_162500119417820.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,380 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:16 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 1,221 | $15.00 | $18,315.73 |
DisclosureSEC source: 0001626199-21-000078 · wf-form4_162163178338161.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,853 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2021 Filed May 21, 2021 21:16 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 50,965 | $15.03 | $765,917.31 |
DisclosureSEC source: 0001626199-21-000078 · wf-form4_162163178338161.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,074 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2021 Filed May 14, 2021 21:17 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $11.52 | $115,169.00 |
DisclosureSEC source: 0001626199-21-000072 · wf-form4_162102700497745.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $11.34 to $11.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provideupon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:17 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $11.68 | $116,842.00 |
DisclosureSEC source: 0001626199-21-000072 · wf-form4_162102700497745.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.57 to $11.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provideupon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 22:09 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $10.52 | $105,200.00 |
DisclosureSEC source: 0001626199-21-000042 · wf-form4_161852457474484.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $10.50 to $10.6450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 22:09 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $10.07 | $100,714.00 |
DisclosureSEC source: 0001626199-21-000042 · wf-form4_161852457474484.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.3075. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 22:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $12.99 | $129,875.00 |
DisclosureSEC source: 0001626199-21-000033 · wf-form4_161524086755922.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.85 to $13.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $13.01 | $130,108.00 |
DisclosureSEC source: 0001626199-21-000033 · wf-form4_161524086755922.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.82 to $13.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 10,000 | $11.74 | $117,381.00 |
DisclosureSEC source: 0001626199-21-000031 · wf-form4_161238964694728.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $11.64 to $12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 7,021 | $13.20 | $92,697.56 |
DisclosureSEC source: 0001626199-21-000031 · wf-form4_161238964694728.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.05 to $13.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 2,979 | $12.07 | $35,967.85 |
DisclosureSEC source: 0001626199-21-000031 · wf-form4_161238964694728.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,060 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.66 to $12.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 01:03 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 255,000 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001626199-21-000028 · wf-form4_160998141101682.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2031-01-04 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 01:37 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Tax withholdingCommon Stock | 11,123 | $12.60 | $140,149.80 |
DisclosureSEC source: 0001626199-21-000004 · wf-form4_160981064946872.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,039 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 22:30 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 260,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034854 · doc4.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,162 F4 · kind: Acquisition by the Reporting Person pursuant to the Distribution. F4 · price: Acquisition by the Reporting Person pursuant to the Distribution. F5 · balance_after: Includes 33,785 RSUs that represent contingent rights to receive 33,785 shares of the Issuer's common stock upon settlement. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 22:30 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 993,801 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034854 · doc4.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alpine ImmunoSciences, L.P. Disclosed balance after: 3,000,980 F1 · kind: Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the "Distribution"). F1 · price: Alpine ImmunoSciences, L.P. distributed these shares to its limited partners on a pro rata basis for no consideration (the "Distribution"). F2 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 23:24 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Tax withholdingCommon Stock | 8,227 | $9.71 | $79,884.17 |
DisclosureSEC source: 0000899243-20-018173 · doc4.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,634 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Certain of these securities are restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 23:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (right to buy) · Derivative | 270,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0000899243-20-002067 · doc4.xml · derivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2030-01-22 F4 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 23:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 67,569 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002067 · doc4.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,861 F1 · price: Received a grant of restricted stock units ("RSUs") pursuant to the 2018 Equity Incentive Plan for no consideration. The RSUs were granted in lieu of cash incentive compensation achieved pursuant to the terms of the Company's Executive Incentive Compensation Plan. Fifty percent (50%) of the RSUs will vest on June 30, 2020 and fifty percent (50%) of the RSUs will vest on December 31, 2020, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 23, 2019 Filed Jan 27, 2020 23:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002067 · doc4.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292 Read SEC document |
| December 11, 2019 Filed Jan 27, 2020 23:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002067 · doc4.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,292 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:30 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $6.51 | $0.00 |
DisclosureSEC source: 0000899243-19-003032 · doc4.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-05 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 01:44 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseWarrant (right to buy) · Derivative | 74,441 | Not disclosed Strike: $12.74 | Not disclosed |
DisclosureSEC source: 0000899243-19-001662 · doc4.xml · derivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 74,441 Underlying: Common Stock · 74,441 shares Expires 2024-01-18 F1 · kind: Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock. F2 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F2 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 01:44 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 190,875 | $5.37 | $1,024,998.75 |
DisclosureSEC source: 0000899243-19-001662 · doc4.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Alpine ImmunoSciences, L.P. Disclosed balance after: 3,994,781 F1 · kind: Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock. F2 · ownership.direct: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F2 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 21, 2018 Filed Jan 23, 2019 01:44 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001662 · doc4.xml · nonDerivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,292 Read SEC document |
| May 15, 2018 Filed Jan 23, 2019 01:44 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001662 · doc4.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,292 Read SEC document |
| May 14, 2018 Filed Jan 23, 2019 01:44 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001662 · doc4.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,292 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:21 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 70,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0000899243-18-000495 · doc4.xml · derivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantEmployee Stock Option (right to buy) · Derivative | 208,916 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · derivative · entry 8 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,916 Underlying: Common Stock · 208,916 shares Expires 2027-04-11 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.exercise_price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F5 · price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F7 · derivative.exercise_date: This option vests 25% on January 20, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.underlying_shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantEmployee Stock Option (right to buy) · Derivative | 300,624 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · derivative · entry 7 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,624 Underlying: Common Stock · 300,624 shares Expires 2027-03-13 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.exercise_price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F5 · price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F7 · derivative.exercise_date: This option vests 25% on January 20, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.underlying_shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantEmployee Stock Option (right to buy) · Derivative | 51,242 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · derivative · entry 6 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,242 Underlying: Common Stock · 51,242 shares Expires 2025-12-15 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.exercise_price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F5 · price: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. F6 · derivative.exercise_date: The Reporting Person was initially granted an option to acquire 300,000 shares, 150,000 shares of which vested on May 16, 2016, and the remaining shares vested or vest in 32 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F5 · derivative.underlying_shares: Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 3,803,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · nonDerivative · entry 5 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Alpine Immunosciences, L.P. Disclosed balance after: 3,803,906 F1 · kind: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F3 · ownership.nature: Alpine BioVentures GP, LLC is the general partner of Alpine Immunosciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine Immunosciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine Immunosciences, L.P. and as a result may be deemed to have beneficial ownership of such shares. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 23,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · nonDerivative · entry 4 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,292 F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 24,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · nonDerivative · entry 3 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mitch & Dawn Gold Irrevocable Trust fbo Simon P. Gold Disclosed balance after: 24,845 F1 · kind: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · ownership.nature: Bradley Hurwitz serves as the trustee for these trusts. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 24,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · nonDerivative · entry 2 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mitch & Dawn Gold Irrevocable Trust fbo Noah M. Gold Disclosed balance after: 24,845 F1 · kind: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · ownership.nature: Bradley Hurwitz serves as the trustee for these trusts. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 21:13 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 24,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019069 · doc4.xml · nonDerivative · entry 1 GOLD MITCHELL · CIK 0001242882 · Director · Executive Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mitch & Dawn Gold Irrevocable Trust fbo Aidan J. Gold Disclosed balance after: 24,845 F1 · kind: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F1 · price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. ("Old Alpine"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the "Exchange Ratio"). F2 · ownership.nature: Bradley Hurwitz serves as the trustee for these trusts. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.